Custirsen Sodium

库司替森钠

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameCustirsen Sodium
Drug Alias Name库司替森OGX-011TV-1011ISIS-112989
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionClusterin inhibitors
TargetsClusterin
Therapy Area/IndicationsCardiac Conduction System DiseaseProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[21] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesThe University Of British Columbia
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAchieve Life Sciences IncThe University Of British ColumbiaTeva Pharmaceutical Industries Ltd +[4] 
Active IndicationsN/A
Inactive IndicationsCardiac Conduction System DiseaseProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[4] 

Other Information

ATC CodeN/A
Related LinksKEGG